RECRUITING

Investigating the Impact of Duration and Amount of Light on the Circadian System Response - Aim 3

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Investigate the long-term impact of amount and duration of Tailored Lighting Intervention (TLI) obtained from Aims 1 and 2 on sleep, cognition, circadian marker, mood, and behavior in AD/ADRD patients. For this single-arm, randomized, placebo-controlled study, the researchers plan to recruit 100 participants who will experience either the active TLI or the placebo for 6 months.

Official Title

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 3

Quick Facts

Study Start:2024-12-03
Study Completion:2027-01-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06595030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score \<25
  2. * Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5
  1. * Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
  2. * Obstructing cataracts
  3. * Severe macular degeneration
  4. * Use of sleep medication
  5. * Use of oral melatonin
  6. * untreated moderate to severe sleep apnea
  7. * Severe restless leg syndrome - Blindness

Contacts and Locations

Study Contact

Barbara Plitnick, BSN
CONTACT
518-242-4603
Barbara.Plitnick@mountsinai.org
Mariana Figueiro, PhD
CONTACT
212-241-6500
mariana.figueiro@mountsinai.org

Principal Investigator

Mariana Figueiro, PhD
PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai

Study Locations (Sites)

Icahn School of Medicine at Mount Sinai
Menands, New York, 12204
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States

Collaborators and Investigators

Sponsor: Icahn School of Medicine at Mount Sinai

  • Mariana Figueiro, PhD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-03
Study Completion Date2027-01-31

Study Record Updates

Study Start Date2024-12-03
Study Completion Date2027-01-31

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer's Disease
  • Mild Cognitive Impairment